Microgyn

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Microgyn

Quick Facts

Property Description
Active Ingredients Ethinylestradiol, Levonorgestrel
Form Coated Tablet
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Contraception / Prevention of Pregnancy
Origin Synthetic (both compounds)

What Type of Medicine is Microgyn?

Microgyn is a prescription medication structurally defined as a Combined Oral Contraceptive (COC), belonging to the broader Combined Hormonal Contraceptive (CHC) class. Its primary therapeutic goal is the systemic prevention of pregnancy in women of reproductive age. The product is administered orally and is supplied as a coated tablet.

The medication is officially classified within the pharmacotherapeutic group of progestogens and oestrogens, fixed combinations. This fixed, dual-hormone structure positions Microgyn as a method of reversible contraception. The general use scenario involves its routine administration to manage and prevent conception in healthy adult women seeking family planning.

Composition and Origin: The Ethinylestradiol and Levonorgestrel Combination

The composition of Microgyn is based on its two active ingredients: Ethinylestradiol (a synthetic estrogen) and Levonorgestrel (a synthetic progestogen). Both active components are chemically synthesized, defining the preparation's synthetic origin.

As a combination product, it delivers the hormones in a set ratio, a characteristic that differentiates it from single-hormone formulations. The combination of Ethinylestradiol with the second-generation progestogen, Levonorgestrel, is a recognized combination within the combined contraceptive category.

How This Combination Delivers Contraception

The function of combining Ethinylestradiol and Levonorgestrel is to utilize a synergistic effect that interrupts the biological processes necessary for fertilization and implantation. The outcome of this dual-hormone regimen is the consistent prevention of pregnancy. By leveraging the systematic effect of these synthetic sex hormones, the formulation provides a means of achieving the general therapeutic goal of reliable, reversible contraception.

What side effects are possible with Microgyn?

Possible side effects and safety information

The safety profile of Microgyn, a Combined Oral Contraceptive (COC) containing Ethinylestradiol and Levonorgestrel, is defined by regulatory classifications that structure the occurrence and type of adverse reactions . These events are categorized by frequency and the physiological systems affected, consistent with official prescribing information.

Classification of Officially Documented Adverse Reactions

Adverse reactions span multiple System-Organ Classes (SOCs), including the vascular, nervous, reproductive, and gastrointestinal systems. The official classifications include:

  • Very Common Reactions: Include headache and spotting or breakthrough bleeding, which is often noted to occur more frequently during the initial cycles of treatment.
  • Common Reactions: Documented effects include nausea, abdominal pain, breast tenderness, mood changes (including depression), and weight changes.
  • Rare Reactions: These low-frequency events include Venous Thromboembolism (VTE), such as Deep Vein Thrombosis and Pulmonary Embolism, Arterial Thromboembolism (ATE) (e.g., myocardial infarction, stroke), and the development of hepatic adenomas (benign liver tumors).

Serious Safety Constraints

Regulatory documents establish specific population-based constraints due to serious risks. The medication is contraindicated in women over 35 years of age who smoke due to the significantly increased risk of serious cardiovascular events. It is also restricted for use in individuals with pre-existing conditions such as severe hepatic impairment or a history of thromboembolic disorders or migraine with aura.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Microgyn (Ethinylestradiol and Levonorgestrel) is defined by official regulatory bodies as generally having low acute toxicity. Acute symptoms are often limited, and the outcome is officially classified as unlikely to be life-threatening.

Documented Overdose Manifestations Required Emergency Actions
Nausea and vomiting Seek immediate medical attention
Withdrawal/Vaginal bleeding Contact emergency services
Breast tenderness, headache, drowsiness Call a poison control center
Giddiness, abdominal pain, rash Monitoring of vital signs is necessary

Regulatory documents confirm that overdose manifestations, including withdrawal bleeding, have been noted to occur in women and girls. Immediate medical attention is mandated because, while severe outcomes are rare, official labeling confirms there is no specific antidote known for this hormonal combination. Management procedures therefore require symptomatic and supportive treatment, including continuous monitoring of vital signs during acute management. The official overdose profile for this combined hormonal contraceptive is primarily focused on managing these limited, documented clinical signs, consistent with the low acute toxicity classification.

Therapeutic Uses of Microgyn

What Microgyn Treats: Main Uses and Benefits

The medication is applied to provide supportive benefits across relevant symptomatic domains. Within its pharmacological category, the medicine is commonly used to help manage symptoms in relevant clinical contexts.

Microgyn plays a role in managing symptoms that create noticeable physiological strain and where functional stability becomes affected. It supports the management of symptom clusters that may appear suddenly or fluctuate. Common categories of conditions where it is applied include those characterized by periods of heightened symptoms, recurrent or episodic manifestations, and functional stress.

“The medicine is applied across domains where additional symptomatic support is needed, providing support that helps ease the overall symptom burden.”

Applied in Addressing Acute Symptom Discomfort

This domain addresses symptoms related to physical discomfort. It is often used when symptoms intensify and supportive relief is needed, supporting the patient during difficult episodes and assisting with maintaining stability. This provides support that helps patients cope more steadily with symptom fluctuations and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Physical Discomfort

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Microgyn

Microgyn is intended for females of reproductive potential seeking pregnancy prevention. Eligibility is strictly governed by regulatory criteria that define absolute contraindications based on pre-existing health conditions and risk factors.

The medication is contraindicated for several high-risk groups. This includes women over 35 years of age who smoke, as this combination significantly increases the risk of serious cardiovascular events. It must also not be used by individuals with a current or history of venous or arterial thromboembolism (blood clots, stroke, heart attack) or a known hereditary predisposition to clotting disorders.

Further absolute contraindications apply to those with severe uncontrolled hypertension, diabetes with vascular damage, current or previous severe hepatic disease or liver tumours, and known hormone-dependent malignant tumours.

Use is contraindicated during pregnancy and not recommended while breastfeeding. Additionally, the medication must be temporarily discontinued at least four weeks before and two weeks after any major surgery or period of prolonged immobilization. Use in pre-menarcheal and elderly populations is classified as not applicable.

What should I know about interactions with other medicines?

The interaction profile for Microgyn is strictly defined by its documented effects on drug exposure, potential for diminished contraceptive effectiveness, and formally prohibited combinations, as detailed in regulatory documents.

Formal Restrictions and Contraindicated Combinations

Co-administration is strictly restricted with specific Hepatitis C Virus (HCV) treatments. These include medicinal products containing ombitasvir/paritaprevir/ritonavir (with or without dasabuvir), and those containing glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir. These combinations are formally contraindicated due to the documented risk of liver enzyme elevations.

Altered Systemic Exposure

Certain medicines and substances are known to modify the concentration of Microgyn’s hormones. Metabolic enzyme inducers such as specific anticonvulsants (e.g., phenytoin, carbamazepine) and the herbal product St. John's Wort are documented to decrease the plasma concentrations, which may reduce effectiveness. Conversely, CYP3A inhibitors like certain antifungals (e.g., itraconazole, fluconazole) and grapefruit juice may increase systemic exposure.

Interaction with Other Medicines

Microgyn is documented to affect the concentrations of co-administered drugs. Its use significantly decreases the plasma concentration of Lamotrigine and can increase the plasma concentration of both Thyroid Hormone and Corticosteroid Replacement Therapies.

Timing Separation Rule

Administration of the bile acid sequestrant Colesevelam must be separated by 4 or more hours from the contraceptive tablets to address the documented decrease in Ethinylestradiol systemic exposure.

Mechanism of Action

How Microgyn Works: Mechanism of Action

Microgyn acts via two primary mechanistic domains: central signaling suppression of reproductive endocrine pathways and the creation of peripheral physical barriers.

Central Inhibition of the HPO Axis

This mechanism involves the active ingredients, levonorgestrel and ethinylestradiol, engaging their respective receptors (PR and ER) in the central hormonal control centers. This interaction generates a pronounced negative feedback signal, resulting in the suppression of the Luteinizing Hormone (LH) surge. This mechanistic consequence is associated with anovulation (the non-release of an egg from the ovary).

️ Modulation of Reproductive Tract Tissue

The peripheral actions are mediated primarily by the progestin component, targeting receptors in the cervix and uterus. This action significantly increases the viscosity of cervical mucus and alters the morphology of the uterine lining (endometrium). These two peripheral physiological changes result in the impeding of sperm transit and a reduction in uterine receptivity.

Molecular Synergy and Systemic Protein Dynamics

The ingredients act in concert (synergy) to reinforce HPO axis suppression. The estrogen component also modulates hepatic protein synthesis, altering the distribution of hormone-binding proteins. This systemic effect acts in concert with the central and peripheral mechanisms.

Dosage and Administration Information

Administration Guidelines

Microgyn, a combined hormonal contraceptive, is administered orally in a fixed-dose, cyclic regimen. The dosage is one coated tablet containing 30 mu g Ethinylestradiol and 150 mu g Levonorgestrel per active day.


Dosage Schedule and Frequency

Instruction Detail
Route of administration Oral
Dosing schedule One active tablet daily for 21 consecutive days.
Timing in relation to meals Independent of food (may be taken with or without food).
Special procedural conditions The tablet must be taken at approximately the same time each day and in the sequence stated on the blister pack.

Course Duration and Special Circumstances

The standard administration cycle involves taking the active tablets for 21 days, followed by a 7-day tablet-free interval, after which a new pack is started immediately. Withdrawal bleeding typically occurs during this tablet-free period.

Postpartum Initiation: Tablet-taking should generally commence 21 to 28 days following childbirth, provided the patient is not breastfeeding. If administration begins later than day 28, a barrier method must be used for the first seven days of tablet-taking.

Missed Dose Instructions: If an active tablet is missed by more than 12 hours past the usual time, the contraceptive protection may be reduced. The last missed tablet should be taken immediately, and a barrier method must be used additionally for the next seven days. If vomiting or severe diarrhea occurs within 3–4 hours of taking a tablet, the same instructions for a missed tablet apply.


These instructions establish a continuous, structured protocol requiring high daily adherence to maintain the labeled use pattern. The 21-day active phase and 7-day hormone-free interval define the fixed, long-term cyclic regimen for administration.

Recent Clinical Evidence

Recent Clinical Evidence: Contraception and Safety

Contraceptive Efficacy and Mechanism

Microgyn, a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel, functions primarily by preventing the release of an egg from the ovary (ovulation). Research has explored its dual action, which involves suppressing the luteinizing hormone (LH) surge and affecting cervical mucus consistency. Studies demonstrate that when used as directed, formulations containing levonorgestrel and ethinylestradiol (at doses of 35 micrograms or less) have a well-established profile for preventing pregnancy.

Non-Contraceptive Outcomes

Clinical data suggest that levonorgestrel-containing COCs may be associated with certain non-contraceptive health outcomes. These formulations have been studied in relation to conditions such as acne and hirsutism, with some women reporting improvement in skin condition. Research also suggests a potential association between long-term use of COCs and lower rates of certain cancers, such as ovarian and endometrial cancers, while also being linked to a higher risk of others, such as cervical cancer.

Safety Profile and Risk Evaluation

The most significant safety consideration for COCs, supported by extensive epidemiological data, is the associated risk of venous thromboembolism (VTE). The risk of VTE is primarily driven by the estrogen component (ethinylestradiol), though the risk is significantly lower than the risk associated with pregnancy and the immediate postpartum period. Clinical guidelines generally regard low-dose ethinylestradiol/levonorgestrel pills as having a favorable balance of benefits and risks, particularly when screened for individual risk factors. Common adverse effects reported in trials include headache, nausea, and changes in bleeding patterns, which often diminish over the initial months of use.

Key Studies & References Combined oral contraceptive use and the risk of cancer: a systematic review

Frequently Asked Questions (FAQ)

Common questions about Microgyn (FAQ)

Q: What is Microgyn used for, besides its main listed purpose?

According to the official product information, the primary purpose of Microgyn is contraception. Studies have also examined potential associations with secondary, non-contraceptive health outcomes. These include reported improvements in conditions like acne and hirsutism, as well as changes in the risk of certain cancers.

Q: How long do the effects of Microgyn last?

The contraceptive effect is intended to be continuous, provided the tablet is taken daily as prescribed. Pharmacokinetic data indicates that the half-life of the active ingredients supports a daily dosing regimen for maintenance of the required plasma concentrations. This is why official guidelines emphasize taking the pill at approximately the same time each day.

Q: Are there any long-term side effects associated with using Microgyn?

Regulatory documents discuss potential risks associated with long-term use, particularly the established risk of venous thromboembolism (VTE). Additionally, long-term use is associated with changes in the risk of certain cancers, such as a decreased risk of ovarian and endometrial cancers, and an increased risk of cervical cancer.

Q: Do food or certain supplements impact how Microgyn is absorbed?

Official administration guidelines state that Microgyn may be taken with or without food. However, certain substances are documented to affect the hormone levels in the blood. For example, substances classified as enzyme inducers, such as the herbal product St. John’s Wort, and even grapefruit juice, may alter systemic exposure.

Q: Do the side effects of Microgyn get better over time?

Official documentation for common adverse events, such as spotting or breakthrough bleeding, frequently notes that these symptoms tend to occur more often during the initial cycles of use. This suggests that some temporary side effects may lessen as the body adjusts to the medication.

Q: Does Microgyn have any known contraindications with herbal supplements?

Yes, official regulatory documents state that the herbal product St. John's Wort (Hypericum perforatum) is restricted from co-administration. It is documented as an enzyme inducer that can reduce the effectiveness of Microgyn.

Q: Are there any specific dietary restrictions mentioned for Microgyn?

The only specific dietary item mentioned in relation to Microgyn's hormone concentrations is grapefruit juice. Consuming grapefruit juice is restricted as it may increase the systemic exposure of the hormones.

Q: How does the age of a person impact the way Microgyn works?

The contraceptive mechanism of Microgyn is generally consistent across the reproductive age range. However, official warnings specifically state that women over 35 years of age who smoke have a significantly increased risk of serious cardiovascular events, which restricts use in this specific population.

Q: Does Microgyn affect blood sugar levels?

Regulatory documents list the presence of diabetes mellitus with vascular damage as a contraindication for using Microgyn. Combined Oral Contraceptives are known to sometimes affect glucose tolerance, meaning they may influence the body's ability to manage blood sugar, which requires careful consideration in patients with pre-existing diabetes.

Q: How quickly does Microgyn start to work after the first use?

For a new user starting the medication, contraceptive protection is generally described in official regulatory text as beginning after seven consecutive days of active pill-taking. Non-hormonal contraception methods are often recommended during this initial period to ensure protection.

Q: Is it common to feel tired while taking Microgyn?

Fatigue is not listed among the most common adverse reactions, such as headache or nausea, in official documentation. It is sometimes listed as an uncommon or rare side effect.

Q: Can Microgyn cause skin reactions or a rash?

Yes, official documentation lists certain skin reactions as documented adverse reactions. These events, which are typically categorized as rare or very rare, include rash, hives (urticaria), and erythema nodosum.

Q: Can I take pain relievers like ibuprofen with Microgyn?

Official drug interaction information generally does not identify common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or aspirin as having a clinically significant interaction. This means these pain relievers are usually not documented as impacting contraceptive effectiveness.

Q: Is it safe to drink alcohol while using Microgyn?

Official guidance generally does not list an interaction between alcohol consumption and Microgyn that affects its effectiveness.

Q: What happens if I stop using Microgyn suddenly?

Upon stopping Microgyn, the hormonal effect is removed. Official product information describes the potential for a return to ovulation to occur shortly after cessation, which means contraceptive protection is immediately lost.

Q: Is Microgyn a controlled substance or addictive?

Microgyn is a hormonal contraceptive and is not classified as a controlled substance under regulatory frameworks. Furthermore, it is not associated with physical dependence or addictive potential.

Q: Are there different brand names for a drug with the same active ingredients as Microgyn?

Yes, because Microgyn contains a fixed combination of well-established active hormones (Ethinylestradiol and Levonorgestrel), multiple brand names and generic versions of this formulation exist globally.

Q: What is the risk of an allergic reaction to Microgyn?

Regulatory documents report the occurrence of hypersensitivity reactions (allergic reactions), which are typically categorized as rare adverse events.

Q: Does Microgyn affect my ability to drive or operate machinery?

Official regulatory documents state that Microgyn is documented as having no or negligible influence on the ability to drive or use machines.

Q: How is Microgyn eliminated from the body?

The active hormones are processed (metabolized) primarily in the liver. They are subsequently eliminated from the body and excreted in the urine and bile (via feces) as inactive compounds.

Q: Can I use over-the-counter cold medicines with Microgyn?

Official interaction documentation focuses on specific mechanisms (like enzyme induction) that could impact hormone levels. General over-the-counter cold medicines are usually not listed as having clinically relevant interactions that affect contraceptive efficacy.

Q: Is it possible to become resistant to the effects of Microgyn over a long time?

Regulatory data supports the long-term effectiveness of the drug. There are no official reports or regulatory statements indicating that the contraceptive mechanism develops resistance or tolerance over time.

Q: What happens if I accidentally take two doses of Microgyn close together?

Official overdose information states that serious harmful effects have not been reported following ingestion of large doses. Potential symptoms that may occur include nausea, vomiting, and breakthrough bleeding.

Q: Is Microgyn available in generic form?

Yes, because the combination of Ethinylestradiol and Levonorgestrel is well-established, generic versions of the Microgyn formulation are available in many jurisdictions, subject to local regulatory approval.

Q: Why do some people report feeling lightheaded after using Microgyn?

Official regulatory documents sometimes list dizziness or vertigo as an uncommon or rare side effect. This may be the explanation for reports of feeling lightheaded.

Q: What information is available regarding Microgyn use in patients with kidney problems?

Official documents do not list severe renal impairment (kidney problems) as an absolute contraindication for Microgyn. However, specific warnings may exist regarding fluid retention.

Q: Does taking Microgyn require regular blood tests or monitoring?

Regulatory guidance recommends certain medical examinations and monitoring before and during use. This typically includes checking blood pressure, and the monitoring of liver function and glucose tolerance (blood sugar management) if applicable.

How should Microgyn be stored and disposed of?

How to Store and Dispose of Microgyn

Official regulatory guidance dictates specific conditions for storing and disposing of Microgyn to maintain its stability and effectiveness.

Storage Requirements

Condition Requirement
Temperature Store below 30 C (Controlled Room Temperature).
Protection Keep in a cool, dry place, protected from moisture and light.
Packaging Keep the tablets sealed in the original blister pack until use.
Safety Keep the medicine strictly out of the reach of children.

️ Disposal Requirements

Expired or unused Microgyn must not be thrown into household trash or flushed down the toilet. Disposal must follow regulatory guidelines for pharmaceutical waste. To comply with official instructions, return any unused medicine to a local pharmacy or an approved drug take-back program for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Microgyn found in:

A-Z Index: